NVAX

Novavax Inc. Healthcare - Biotechnology Investor Relations →

YES
21.3% BELOW
↓ Approaching Was -17.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $12.22
14-Week RSI 74
Rel. Volume (14w) This week's trading vs. the 14-week average 1.2x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.97

Novavax Inc. (NVAX) closed at $9.62 as of 2026-03-20, trading 21.3% below its 200-week moving average of $12.22. This places NVAX in the extreme value zone. The stock is currently moving closer to the line, down from -17.7% last week. With a 14-week RSI of 74, NVAX is in overbought territory.

Trading volume is running at 1.2x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.97 ratio) is neutral — neither side is clearly dominating.

Over the past 1532 weeks of data, NVAX has crossed below its 200-week moving average 17 times. On average, these episodes lasted 62 weeks. The average one-year return after crossing below was -10.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $1567 million, NVAX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at -12.2x book value.

Share count has increased 89.0% over three years, indicating dilution.

Over the past 29.4 years, a hypothetical investment of $100 in NVAX would have grown to $14, compared to $1419 for the S&P 500. NVAX has returned -6.5% annualized vs 9.4% for the index, underperforming the broader market over this period.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: NVAX vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After NVAX Crosses Below the Line?

Across 17 historical episodes, buying NVAX when it crossed below its 200-week moving average produced an average return of -20.2% after 12 months (median -40.0%), compared to +10.8% for the S&P 500 over the same periods. 24% of those episodes were profitable after one year. After 24 months, the average return was +17.6% vs +22.1% for the index.

Each line shows $100 invested at the moment NVAX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

NVAX has crossed below its 200-week MA 17 times with an average 1-year return of +-10.8% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Nov 1996Jul 19973435.6%+28.6%-86.3%
Jul 1997Jul 199712.0%-23.6%-89.3%
Nov 1997Dec 199747.5%-33.3%-89.3%
Feb 1998Sep 19998167.9%-42.3%-89.2%
Oct 1999Oct 199915.7%+110.3%-87.6%
Apr 2002Sep 20037571.0%-31.4%-91.8%
Oct 2003Jan 200611782.4%-47.8%-93.4%
Jul 2006Oct 20061324.2%-23.6%-87.9%
Dec 2006Oct 20074137.4%-10.8%-87.9%
Nov 2007Jul 20098982.5%-37.2%-86.6%
Nov 2009Oct 201215050.6%-29.6%-85.3%
Oct 2012Mar 20132226.4%+36.5%-77.2%
Apr 2013Jul 2013914.5%+98.6%-77.9%
Feb 2016Mar 201664.5%-72.3%-90.0%
May 2016May 2016213.0%-83.9%-89.6%
Sep 2016May 202019192.0%-11.6%-62.7%
Feb 2022Ongoing212+95.3%Ongoing-86.6%
Average62+-10.8%

Frequently Asked Questions

Is NVAX below its 200-week moving average?

Yes. As of 2026-03-20, Novavax Inc. (NVAX) is trading 21.3% below its 200-week moving average of $12.22. The current price is $9.62.

What is NVAX's 200-week moving average price?

Novavax Inc.'s 200-week moving average is $12.22 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when NVAX drops below its 200-week moving average?

NVAX has crossed below its 200-week moving average 17 times in our data. The average one-year return after these crossings was -10.8%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 62 weeks on average.

Is NVAX a good value right now?

Here's what our data says about NVAX as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 74 (overbought). Free cash flow is currently negative. Price-to-book is -12.2x. This is not a buy or sell recommendation — always do your own research.

How does NVAX compare to the S&P 500?

Over the past 29.4 years, $100 invested in NVAX would have grown to $14, compared to $1419 for the S&P 500. That's -6.5% annualized vs 9.4% for the index. NVAX has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20